Oxford Biomedica (OXB) Competitors

Genus (LON:GNS) and Oxford Biomedica (LON:OXB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Is GNS or OXB more profitable?

Genus has a net margin of 1.18% compared to Oxford Biomedica's net margin of -145.98%. Genus' return on equity of 1.41% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genus	1.18%	1.41%	3.31%
Oxford Biomedica	-145.98%	-202.50%	-12.67%

Do analysts prefer GNS or OXB?

Genus presently has a consensus target price of GBX 2,150, indicating a potential upside of 6.44%. Oxford Biomedica has a consensus target price of GBX 380, indicating a potential upside of 14.46%. Given Oxford Biomedica's higher possible upside, analysts plainly believe Oxford Biomedica is more favorable than Genus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genus	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Does the media refer more to GNS or OXB?

In the previous week, Oxford Biomedica had 1 more articles in the media than Genus. MarketBeat recorded 2 mentions for Oxford Biomedica and 1 mentions for Genus. Genus' average media sentiment score of 0.30 beat Oxford Biomedica's score of 0.00 indicating that Genus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oxford Biomedica	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more risk and volatility, GNS or OXB?

Genus has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500. Comparatively, Oxford Biomedica has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500.

Does the MarketBeat Community prefer GNS or OXB?

Oxford Biomedica received 6 more outperform votes than Genus when rated by MarketBeat users. However, 70.60% of users gave Genus an outperform vote while only 66.73% of users gave Oxford Biomedica an outperform vote.

Company	Underperform	Outperform
Genus	Outperform Votes 353 70.60%	Underperform Votes 147 29.40%
Oxford Biomedica	Outperform Votes 359 66.73%	Underperform Votes 179 33.27%

Do insiders & institutionals believe in GNS or OXB?

77.8% of Genus shares are held by institutional investors. Comparatively, 64.1% of Oxford Biomedica shares are held by institutional investors. 0.8% of Genus shares are held by company insiders. Comparatively, 21.2% of Oxford Biomedica shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Which has better earnings and valuation, GNS or OXB?

Genus has higher revenue and earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genus	£666.67M	1.98	£7.87M	£12.06	167.44
Oxford Biomedica	£98.31M	3.59	-£143.51M	-£134.59	-2.47

Summary

Genus beats Oxford Biomedica on 12 of the 18 factors compared between the two stocks.